Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Ig Sanita Pubbl ; 71(5): 477-87, 2015.
Article in Italian | MEDLINE | ID: mdl-26722825

ABSTRACT

The study evaluated oral hygiene knowledge among a group of 12-year-old students in Lombardy, Italy (n=182). Two different questionnaires were administered, respectively to adolescents and to their parents. Results indicate a low level of general knowledge on this topic. Factors influencing knowledge include the number of learning sources and yearly access to a dental clinic. The described situation highlights the need to implement school-based educational interventions.


Subject(s)
Adolescent Behavior/psychology , Health Knowledge, Attitudes, Practice , Oral Hygiene/psychology , Parents/psychology , Students/psychology , Adolescent , Adult , Child , Dental Care for Children/psychology , Female , Health Promotion , Health Surveys , Humans , Italy/epidemiology , Male , Oral Hygiene/statistics & numerical data , Reproducibility of Results , Students/statistics & numerical data , Surveys and Questionnaires
2.
ScientificWorldJournal ; 2014: 174282, 2014.
Article in English | MEDLINE | ID: mdl-24578620

ABSTRACT

Dementia is a leading health problem worldwide, with Alzheimer's disease (AD) representing up to 60% of all dementia cases. A growing interest has recently risen on the potential use of natural molecules in this condition. Curcumin is a polyphenolic compound traditionally used in Indian medicine. Several in vitro and in vivo studies have found a protective effect of curcumin in AD. In the present systematic review we aimed to evaluate the state-of-the-art of clinical trials of curcumin in AD. We retrieved three published studies, while there are several ongoing clinical trials. To date there is insufficient evidence to suggest the use of curcumin in dementia patients. Of note, short-term use of curcumin appears to be safe. Several reasons could be responsible for the discrepancy between in vitro and in vivo findings and human trials, such as low bioavailability and poor study design.


Subject(s)
Alzheimer Disease/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Curcumin/therapeutic use , Clinical Trials as Topic , Humans
3.
Hum Vaccin Immunother ; 10(5): 1204-10, 2014.
Article in English | MEDLINE | ID: mdl-24603089

ABSTRACT

Although influenza vaccination is recognized to be safe and effective, recent studies have confirmed that immunization coverage among health care workers remain generally low, especially among medical residents (MRs). Aim of the present multicenter study was to investigate attitudes and determinants associated with acceptance of influenza vaccination among Italian MRs. A survey was performed in 2012 on MRs attending post-graduate schools of 18 Italian Universities. Each participant was interviewed via an anonymous, self-administered, web-based questionnaire including questions on attitudes regarding influenza vaccination. A total of 2506 MRs were recruited in the survey and 299 (11.9%) of these stated they had accepted influenza vaccination in 2011-2012 season. Vaccinated MRs were older (P = 0.006), working in clinical settings (P = 0.048), and vaccinated in the 2 previous seasons (P<0.001 in both seasons). Moreover, MRs who had recommended influenza vaccination to their patients were significantly more compliant with influenza vaccination uptake in 2011-2012 season (P<0.001). "To avoid spreading influenza among patients" was recognized as the main reason for accepting vaccination by less than 15% of vaccinated MRs. Italian MRs seem to have a very low compliance with influenza vaccination and they seem to accept influenza vaccination as a habit that is unrelated to professional and ethical responsibility. Otherwise, residents who refuse vaccination in the previous seasons usually maintain their behaviors. Promoting correct attitudes and good practice in order to improve the influenza immunization rates of MRs could represent a decisive goal for increasing immunization coverage among health care workers of the future.


Subject(s)
Attitude of Health Personnel , Data Collection , Influenza Vaccines/therapeutic use , Internship and Residency , Physicians , Vaccination/statistics & numerical data , Adult , Data Collection/methods , Female , Humans , Influenza, Human/epidemiology , Influenza, Human/prevention & control , Internship and Residency/trends , Italy/epidemiology , Male , Physicians/trends , Vaccination/trends
4.
Article in English | MEDLINE | ID: mdl-23781271

ABSTRACT

Ginkgo biloba (Gb) has demonstrated antioxidant and vasoactive properties as well as clinical benefits in several conditions such as ischemia, epilepsy, and peripheral nerve damage. Additionally, Gb is supposed to act as potential cognitive enhancer in dementia. So far, several trials have been conducted to investigate the potential effectiveness of Gb in neuropsychiatric conditions. However, the results of these studies remain controversial. We conducted a systematic review and a meta-analysis of three randomised controlled trials in patients with schizophrenia and eight randomised controlled trials in patients with dementia. Gb treatment reduced positive symptoms in patients with schizophrenia and improved cognitive function and activities of daily living in patients with dementia. No effect of Gb on negative symptoms in schizophrenic patients was found. The general lack of evidence prevents drawing conclusions regarding Gb effectiveness in other neuropsychiatric conditions (i.e., autism, depression, anxiety, attention-deficit hyperactivity disorder, and addiction). Our data support the use of Gb in patients with dementia and as an adjunctive therapy in schizophrenic patients.

5.
Curr Vasc Pharmacol ; 8(1): 86-92, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19485931

ABSTRACT

The expression of the Receptor for Advanced Glycation Endproducts (RAGE) is upregulated at sites of vascular inflammation and plays a crucial role in vessel homeostasis. Soluble RAGE (sRAGE), a truncated soluble form of the receptor, acts as a decoy and prevents the inflammatory response mediated by RAGE activation. sRAGE has recently emerged as a biomarker in several RAGE-mediated vascular disorders, including coronary artery disease, hypertension, diabetic vasculopathy and Kawasaki disease. Given the pivotal role played by RAGE and sRAGE in numerous vascular disorders, there is a growing need to understand how drugs can modulate the RAGE axis in different disease conditions. In this regard, there is evidence to suggest that traditional cardiovascular drugs (statins, thiazolidinediones, ACE-inhibitors, AT-1 receptor antagonists) as well as nutraceuticals (grape seed proanthocyanidin extract) could modulate RAGE expression and circulating sRAGE levels in cardiovascular disease states characterized by enhanced RAGE activation. Additionally, the production of genetically engineered sRAGE may hold promise for targeting the activation of RAGE by proinflammatory ligands in the setting of vascular inflammation. The present review considers current vascular drugs as modulators of the RAGE axis, and highlights future directions in the context of RAGE-directed therapy in cardiovascular disease.


Subject(s)
Receptors, Immunologic/agonists , Receptors, Immunologic/antagonists & inhibitors , Vasculitis/drug therapy , Alternative Splicing , Animals , Biomarkers/blood , Cardiovascular Diseases/blood , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/physiopathology , Cardiovascular Diseases/therapy , Diabetic Nephropathies/drug therapy , Diabetic Nephropathies/physiopathology , Gene Expression Regulation , Glycation End Products, Advanced/metabolism , Humans , Peptide Fragments/agonists , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/metabolism , Peptide Fragments/therapeutic use , Phytotherapy , Protein Isoforms/agonists , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/metabolism , Protein Isoforms/therapeutic use , Protein Processing, Post-Translational , Receptor for Advanced Glycation End Products , Receptors, Immunologic/metabolism , Receptors, Immunologic/therapeutic use , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/therapeutic use , Solubility , Vasculitis/physiopathology
6.
N Am J Med Sci ; 1(2): 48-53, 2009 Jul.
Article in English | MEDLINE | ID: mdl-22666669

ABSTRACT

BACKGROUND: Type 1 diabetes is an autoimmune disease. Genetics as well as environmental factors seem to play a role in the pathogenesis of type 1 diabetes. AIMS: We sought to investigate the possible relationship between migration from Sardinia to a low incidence area of type 1 diabetes (Lombardy) and the prevalence of autoantibody positivity. METHODS: We enrolled 554 Sardinian immigrants and 226 of their offspring. All subjects underwent a complete anamnestic evaluation. Fasting blood glucose, HbA1c, GADA and IA-2 were measured in all study participants. Additionally, the presence of risk haplotypes (HLA-DR3 -DR4 and DQB1/0302) was determined. After a seven-year follow-up, high genetic risk and/or autoantibody positivity subjects were re-evaluated. RESULTS: Among Sardinian immigrants, the prevalence of type 1 diabetes was 0.9%, while in the offspring group, the prevalence was 0.4%. After removing type 1 diabetic patients, the GADA prevalence was 2.4% in the immigrant group and 3.8% among their offspring. Among Sardinian immigrants, the IA-2 prevalence was 0.7%, while all offspring were IA-2 negative. After a seven-year follow-up, 85.7% of GADA-positive migrants had persistent GADA positivity. Two GADA-negative offspring subjects turned positive. None of the study participants developed diabetes during the follow-up. CONCLUSIONS: The present study showed a higher prevalence of GADA positivity within Sardinian immigrants at high genetic risk; GADA positivity may represent the first detectable phase of type 1 diabetes. After a seven-year follow-up, none of the high genetic/antibody risk group subjects developed type 1 diabetes. However, it seems reasonable to strictly control high-risk individuals in order to diagnose subclinical diabetes.

7.
J Psychosom Res ; 65(5): 435-9, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18940373

ABSTRACT

OBJECTIVE: Neurotrophins (NT) are a family of closely related proteins, including brain-derived neurotrophic factor, nerve growth factor, neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). NTs are deemed to regulate several aspects of neuronal survival, development, and function. Although NTs have been associated to a variety of mental disorders, the potential role of NT alterations in hypochondriasis (HC) has never been investigated. METHODS: In the present study, plasma concentrations of NTs were evaluated in 23 adult patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria for HC and 22 healthy controls. Platelet serotonin (5-HT) content was chosen as a measure of serotonergic function. Hypochondriacal symptoms were assessed using the Whiteley Index of Hypochondriasis (WIH). RESULTS: Plasma NT-3 level (P=.004) and platelet 5-HT (P=.008) were significantly lower in patients with HC compared with controls. Correlation analyses showed that the WIH score was significantly and inversely associated with both NT-3 values (r=-.60, P=.002) and platelet serotonin content (r=-.53, P=.009). We used a multivariate regression model to determine independent predictors of the WIH score. After allowance for potential confounders, plasma NT-3 levels remained the unique independent predictor of the WIH (beta=.003, t=-3.5, P=.003). CONCLUSIONS: Decreased NT-3 concentration, alongside with serotonin dysfunction, may represent a biological correlate of HC.


Subject(s)
Blood Platelets/metabolism , Hypochondriasis/blood , Neurotrophin 3/blood , Serotonin/blood , Adult , Aged , Brain/metabolism , Female , Humans , Hypochondriasis/diagnosis , Hypochondriasis/psychology , Male , Middle Aged , Personality Inventory/statistics & numerical data , Psychometrics , Reference Values
8.
Clin Biochem ; 41(12): 981-5, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18538667

ABSTRACT

OBJECTIVES: Recent evidences suggest that the activation of peroxisome proliferator-activated receptor (PPAR)-gamma2, which plays an important role in vascular homeostasis, also regulates the expression of the Receptor for Advanced Glycation End products (RAGE). In turn, low levels of soluble RAGE (sRAGE) have recently emerged as a valuable biomarker of vascular inflammation. The potential alterations in sRAGE concentrations in peripheral arterial disease (PAD), however, have not been yet investigated. The aim of the present study was to clarify whether the Pro12Ala polymorphism of the PPAR-gamma2 gene is related to plasma sRAGE levels and the presence of PAD in nondiabetic Italian individuals. DESIGN AND METHODS: A total of 201 patients with PAD and 201 PAD-free control subjects were investigated. Genotyping of the Pro12Ala polymorphism of the PPAR-gamma2 gene was performed by means of PCR-RFLPs. Plasma sRAGE levels were determined by ELISA. RESULTS: Subjects carrying at least one Ala12 allele of the PPAR-gamma2 gene had lower sRAGE levels (all p values<0.001). The prevalence rate of the Ala12 allele was significantly higher in PAD patients (14.0%) than in controls (8.0%, p=0.009). In multivariate logistic regression analysis after adjustment for potential confounders, the Ala12 allele was significantly and independently associated with the risk of PAD (OR=1.57, 95% CI=1.11-2.65, p=0.021). CONCLUSIONS: Our data indicate that the Ala12 allele of the PPAR-gamma2 gene is associated with lower levels of the soluble decoy receptor sRAGE and the presence of PAD.


Subject(s)
PPAR gamma/genetics , Peripheral Vascular Diseases/genetics , Polymorphism, Genetic , Receptors, Immunologic/blood , Aged , Alanine/genetics , Alleles , Biomarkers/blood , Case-Control Studies , Confidence Intervals , DNA/genetics , Female , Genotype , Humans , Italy , Logistic Models , Male , Middle Aged , Odds Ratio , Peripheral Vascular Diseases/blood , Polymerase Chain Reaction , Proline/genetics , Receptor for Advanced Glycation End Products , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...